Retatrutide: How to Get It and What You Should Know — Rewind Anti-Aging of Miami
← Back to Blog
weight loss · 11 min read

Retatrutide: How to Get It and What You Should Know

Wondering how to get retatrutide? Learn about availability, clinical trial results, alternative weight loss peptides, and how to prepare for this therapy.

By the Rewind medical team
Medically reviewed by Alexia Padron, MSN, APRN, FNP-BC ·
Share:

Retatrutide is generating enormous interest as a potential next-generation weight loss medication. As a triple-agonist peptide that targets three key hormone pathways involved in appetite, metabolism, and energy regulation, it represents a significant leap forward from current medical weight loss programs. Adults on the 12 mg dose lost an average of 24.2% of their body weight in 48 weeks in Phase 2 and 28.3% in 80 weeks in the Phase 3 TRIUMPH-1 trial, which has made it one of the most anticipated medications in the obesity treatment space.

If you are researching retatrutide, you likely have questions about how to access it, what the clinical evidence actually shows, how it compares to existing treatments, and what you should know before considering this therapy. This comprehensive guide addresses all of those questions with current, evidence-based information.

What Is Retatrutide?

Retatrutide (also known by its development name LY3437943) is an investigational medication developed by Eli Lilly and Company. It belongs to a new class of drugs called triple hormone receptor agonists, meaning it simultaneously activates three distinct receptor pathways:

The Three Receptor Targets

GLP-1 (Glucagon-Like Peptide-1) Receptor: This is the same receptor targeted by semaglutide (Ozempic, Wegovy) and is responsible for appetite suppression, delayed gastric emptying, and improved insulin secretion. GLP-1 activation reduces hunger, promotes feelings of fullness, and helps regulate blood sugar.

GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor: This receptor is also targeted by tirzepatide (Mounjaro, Zepbound). GIP activation enhances insulin sensitivity, supports fat metabolism, and may improve how the body processes and stores nutrients. Research in Cell Metabolism has shown that GIP signaling plays a critical role in adipose tissue function and energy homeostasis (Campbell & Drucker, 2015).

Glucagon Receptor: This is the unique receptor that sets retatrutide apart from all currently available weight loss medications. Glucagon activation increases hepatic glucose output and promotes lipolysis (fat breakdown), especially in the liver. In animal studies, glucagon receptor agonism increases energy expenditure on top of reduced food intake (Pocai, Molecular Metabolism, 2014).

The combination of all three pathways creates what researchers describe as a comprehensive metabolic reset — simultaneously reducing caloric intake through appetite suppression, improving how the body processes nutrients, and driving the breakdown of stored fat, especially in the liver.

What Does the Clinical Evidence Show?

Woman in her fifties laughing as she holds up jeans that are now too big

Phase 2 Trial Results

The pivotal Phase 2 clinical trial results for retatrutide were published in The New England Journal of Medicine in June 2023 and generated significant attention from the medical community and general public (Jastreboff et al., 2023).

Key findings from this 48-week, dose-ranging study of 338 adults with obesity:

  • Participants receiving the highest dose (12 mg weekly) lost an average of 24.2% of their body weight in 48 weeks
  • At the 12 mg dose, 100% of participants lost at least 5% of their body weight
  • Approximately 83% of participants on the highest dose lost 15% or more of body weight
  • Waist circumference fell by 19.6 cm on 12 mg, versus 2.6 cm on placebo

To put these numbers in context, here is how retatrutide’s Phase 2 data compares to the landmark trials of existing medications:

MedicationReceptors TargetedWeight LossTrial Duration
Semaglutide 2.4 mg (STEP 1)GLP-114.9%68 weeks
Tirzepatide 15 mg (SURMOUNT-1)GLP-1 + GIP22.5%72 weeks
Retatrutide 12 mg (Phase 2)GLP-1 + GIP + Glucagon24.2%48 weeks

Retatrutide reached its result in a shorter trial than either comparison, which is what has researchers and patients so excited. These are separate trials in different populations, and the larger Phase 3 trials have since confirmed and extended the Phase 2 result (below).

Phase 2 Results in Type 2 Diabetes

A separate Phase 2 study examined retatrutide in adults with type 2 diabetes and obesity. Results published in The Lancet showed significant improvements in both weight and glycemic control (Rosenstock et al., 2023):

  • Participants lost up to 16.9% of body weight (lower than the non-diabetic cohort, consistent with other medication studies)
  • HbA1c reductions of up to 2.02 percentage points, bringing many participants into the normal range
  • Significant improvements in fasting glucose and insulin sensitivity

Phase 3 Trials

Eli Lilly has now reported results from five Phase 3 trials:

  • TRIUMPH-1 — 2,339 adults with obesity or overweight and no diabetes, 80 weeks: 28.3% average weight loss on 12 mg, 25.9% on 9 mg and 19.0% on 4 mg, versus 2.2% on placebo; 45.3% of the 12 mg group lost at least 30%
  • TRIUMPH-4 — 445 adults with obesity and knee osteoarthritis, 68 weeks: 28.7% on 12 mg
  • TRIUMPH-2 — 1,152 adults with type 2 diabetes, 80 weeks: 20.8% on 12 mg
  • TRIUMPH-3 — 1,949 adults with severe obesity and cardiovascular disease, 80 weeks: 22.6% on 12 mg
  • TRANSCEND-T2D-1 (The Lancet, 2026) — 537 adults with type 2 diabetes, 40 weeks: 15.3% on 12 mg, with HbA1c down 1.94 points

Lilly plans to submit retatrutide for U.S. approval in the first quarter of 2027. A head-to-head trial against tirzepatide, TRIUMPH-5, is still running.

How to Get Retatrutide

Retatrutide is not yet sold as a branded prescription medicine. These are the pathways patients encounter today.

Clinical Trial Participation

Eli Lilly’s trials are conducted at research sites across the United States and internationally. Most Phase 3 trials have finished enrolling; ClinicalTrials.gov lists any studies still recruiting and their enrollment criteria.

Eligibility for clinical trials typically requires:

  • BMI of 30 or greater, or BMI of 27 or greater with weight-related comorbidities
  • No recent use of other weight loss medications (washout periods apply)
  • Willingness to attend regular study visits and follow protocols
  • Meeting specific inclusion/exclusion criteria that vary by trial

Expanded Access

Lilly runs an expanded access program (ClinicalTrials.gov NCT07629401) for adults with a BMI of 35 or higher and at least two serious obesity-related complications who have not responded to the best available therapy and cannot join a trial.

Talk to a Medical Provider

Our team can walk you through the retatrutide data and whether it may fit your goals — see our retatrutide page for an overview.

Research Chemical Sources

Numerous online vendors sell retatrutide as a “research chemical” not intended for human consumption. These products carry significant risks including unknown purity, incorrect dosing, contamination, and no medical oversight.

We strongly advise against purchasing retatrutide from unregulated online sources.

Be Careful Where You Get Your Information

The excitement surrounding retatrutide has created a surge in misinformation, unverified claims, and predatory marketing. When evaluating information about retatrutide, consider the following:

  • Verify the source. Rely on peer-reviewed journals (NEJM, The Lancet, JAMA), official clinical trial registries (ClinicalTrials.gov), and communications from Eli Lilly.
  • Check the numbers against the trials. The trial averages are genuinely impressive — 24.2% in Phase 2 and 28.3% in Phase 3 on 12 mg — and individual results vary around them.
  • Avoid unregulated products. Products sold as “retatrutide” online may not contain what they claim, may be impure, or may be incorrectly dosed.
  • Work with qualified providers. A licensed medical provider can help you evaluate the legitimacy of any access pathway and monitor your health if you do obtain treatment.

Side Effects Reported in Clinical Trials

Woman in her fifties drinking a glass of lemon water in her kitchen to stay hydrated

The Phase 2 trials provided initial safety data for retatrutide. Like other incretin-based medications, the most common side effects were gastrointestinal:

Common Side Effects

  • Nausea: Reported in approximately 25-45% of participants depending on dose (most common during titration)
  • Diarrhea: Approximately 20-35% of participants
  • Vomiting: Approximately 10-20% of participants
  • Constipation: Approximately 10-15% of participants
  • Decreased appetite: Common and expected given the mechanism of action

Less Common but Notable Effects

  • Increased heart rate: Dose-dependent increases in resting heart rate peaked around week 24 and then declined
  • Injection site reactions: Mild redness or itching at injection sites
  • Fatigue: Reported by some participants, particularly during dose escalation

Most adverse events were mild to moderate and occurred primarily during the dose escalation phase. Proper titration — starting at a low dose and gradually increasing — was associated with better tolerability (Jastreboff et al., 2023).

In TRIUMPH-1, 11.3% of participants on 12 mg stopped treatment because of side effects, compared with 4.9% on placebo.

Who Would Be a Good Candidate for Retatrutide?

Based on the clinical trial population and the medication’s mechanism, individuals who may benefit most from retatrutide include:

  • Adults with excess weight to lose (the trials enrolled a BMI of 30, or 27 with a weight-related condition; Rewind does not use a BMI cutoff)
  • Patients seeking greater weight loss than what current medications provide
  • Individuals with metabolic dysfunction-associated steatohepatitis (MASH) given the glucagon receptor’s role in liver fat metabolism

Retatrutide may not be appropriate for individuals with a history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe gastrointestinal disorders, or a history of pancreatitis. These contraindications are expected to mirror those of existing GLP-1 medications.

Other Weight Loss Peptides Available Now

Two highly effective, approved options are widely prescribed today:

Semaglutide (Ozempic, Wegovy)

The most widely studied GLP-1 receptor agonist. The STEP trial program demonstrated an average weight loss of 14.9% over 68 weeks (Wilding et al., 2021). Semaglutide also has proven cardiovascular benefits, with the SELECT trial showing a 20% reduction in major adverse cardiovascular events (Lincoff et al., 2023).

Tirzepatide (Mounjaro, Zepbound)

A dual GLP-1/GIP receptor agonist that represents the closest currently available mechanism to retatrutide. The SURMOUNT-1 trial showed an average weight loss of 22.5% at the highest dose over 72 weeks (Jastreboff et al., 2022). Tirzepatide is an excellent option for patients seeking substantial weight loss.

Comprehensive Weight Loss Programs

Medication alone produces the best results when combined with lifestyle modifications. Evidence-based programs that integrate nutrition coaching, exercise guidance, behavioral support, and medical monitoring consistently outperform medication-only approaches.

What You Can Do Now to Prepare

Man in his fifties swimming laps at Coral Gables' Venetian Pool on a bright morning

Even if your goal is to eventually use retatrutide, there is no reason to delay taking action on your weight loss and metabolic health:

  • Start with a medication that fits you now. Beginning treatment with semaglutide or tirzepatide now allows you to make significant progress, and your provider can revisit retatrutide as it becomes more widely available.
  • Establish baseline health metrics. Comprehensive bloodwork, body composition analysis, and metabolic assessment now creates a benchmark for measuring future progress.
  • Build sustainable habits. The lifestyle foundation you create now — nutrition, exercise, sleep, stress management — will amplify the results of any medication, including retatrutide.
  • Work with a qualified provider. Establishing a relationship with a medical team experienced in metabolic health ensures you have trusted guidance when new treatments become available.

How Rewind Anti-Aging Can Help

At Rewind Anti-Aging, we stay at the forefront of metabolic health and weight loss treatments. Our team can help you:

  • Evaluate your options. We assess your health profile, goals, and history to recommend the most appropriate current treatment.
  • Access proven treatments today. Semaglutide and tirzepatide are available through our peptide therapy programs with personalized dosing and comprehensive monitoring.
  • Stay informed on retatrutide. We track clinical trial progress and regulatory developments so our patients have access to new treatments as soon as they become available.
  • Build a comprehensive plan. Our programs integrate medication with nutrition coaching, exercise guidance, and ongoing medical support for sustainable results.

Conclusion

Retatrutide represents a genuinely exciting advance in obesity medicine. A novel triple-agonist mechanism produced 24.2% average body weight loss in 48 weeks in Phase 2 and 28.3% in 80 weeks in Phase 3, and Lilly plans to submit it for U.S. approval in early 2027.

The most important takeaway is that you do not need to wait to take action. Highly effective treatments like semaglutide and tirzepatide are available today and can produce transformative results. Starting treatment now puts you in the best possible position — whether you continue with a current medication or transition to retatrutide when it becomes available.

If you are interested in exploring your weight loss options, Rewind Anti-Aging of Miami offers comprehensive, medically supervised programs designed for lasting results. Book a consultation with our team to discuss which treatment is right for you.


Ready to start losing weight? Rewind Anti-Aging of Miami offers proven medical weight loss programs with semaglutide, tirzepatide, and other advanced therapies available today. Schedule a consultation →

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any weight loss treatment.

References

  1. Jastreboff, A. M., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. The New England Journal of Medicine, 389(6), 514-526.
  2. Rosenstock, J., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial. The Lancet, 402(10401), 529-544.
  3. Campbell, J. E., & Drucker, D. J. (2015). Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism, 22(6), 956-970.
  4. Pocai, A. (2014). Action and therapeutic potential of oxyntomodulin. Molecular Metabolism, 3(3), 241-251.
  5. Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). The New England Journal of Medicine, 384(11), 989-1002.
  6. Lincoff, A. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). The New England Journal of Medicine, 389(24), 2221-2232.
  7. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). The New England Journal of Medicine, 387(4), 327-340.

Frequently Asked Questions

How does retatrutide work?

Retatrutide works by activating three hormone receptors -- GLP-1, GIP, and glucagon -- which help regulate appetite, blood sugar, and fat metabolism. This triple-agonist mechanism targets more metabolic pathways than any other weight loss medication currently available.

Is retatrutide FDA approved?

Not yet. Eli Lilly has reported results from five Phase 3 trials and plans to submit retatrutide for U.S. approval in the first quarter of 2027.

What are the expected side effects of retatrutide?

The most common side effects reported in Phase 2 trials include nausea, diarrhea, vomiting, and constipation. These are similar to other GLP-1 class medications, were generally mild to moderate, and were most common while the dose was being raised.

What are the benefits of retatrutide vs semaglutide?

Retatrutide targets three receptors compared to semaglutide's single GLP-1 receptor. Phase 2 data showed up to 24.2 percent body weight loss in 48 weeks and 28.3 percent in 80 weeks in Phase 3, versus semaglutide's 14.9 percent in 68 weeks in its own trial.

What are the best alternatives to retatrutide available now?

Currently available alternatives include semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro). Both are approved, well-studied, and produce significant weight loss results.

How much weight can you lose on retatrutide?

Phase 2 clinical trial data showed participants on the highest dose lost an average of 24.2 percent of their body weight over 48 weeks. In the Phase 3 TRIUMPH-1 trial, the 12 mg average was 28.3 percent at 80 weeks, and 45 percent of that group lost at least 30 percent, though individual results vary based on starting weight, dosing, and lifestyle factors.

More in weight loss

⚕ Medical Disclaimer

The information on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. All treatments at Rewind Anti-Aging of Miami are performed under the supervision of licensed medical professionals. Individual results may vary. Consult your physician before beginning any new treatment protocol.

Meet our clinical team →

Not sure which treatment is right for you?

Take our free 2-minute assessment and get a personalized recommendation.

Take the Quiz →

Take the Next Step

Our team at Rewind Anti-Aging in Miami is here to help you determine if medical weight loss is right for your goals.

Chat with Rewind AI

We typically reply instantly

Book
Powered by AI — not medical advice
Book Consultation